ischaemiareperfus
ir
injuri
common
featur
sever
diseas
associ
high
morbid
mortal
stroke
myocardi
infarct
damag
tissu
display
cardin
sign
inflamm
microvascular
injuri
unless
resolv
lead
longterm
tissu
damag
associ
dysfunct
current
therapi
limit
often
associ
mani
side
effect
increas
evid
suggest
member
formyl
peptid
receptor
fpr
famili
particular
human
might
import
role
pathophysiolog
ir
injuri
recent
demonstr
sever
peptid
nonpeptidyl
smallmolecul
compound
antiinflammatori
proresolv
properti
via
action
member
fpr
famili
review
evid
suggest
fpr
ligand
particularli
brain
could
novel
excit
antiinflammatori
therapeut
treatment
varieti
clinic
condit
includ
stroke
glossari
lipoxin
lxa
annexin
ntermin
domain
annexin
repres
bioactiv
peptid
span
amino
acid
complement
receptor
also
known
complement
compon
receptor
cluster
differenti
gproteincoupl
receptor
dissoci
constant
k
measur
tightli
ligand
bind
particular
receptor
low
ligand
k
valu
reflect
high
affin
receptor
gproteincoupl
receptor
gpcr
protein
extracellular
domain
intracellular
ctermin
tail
separ
three
extracellular
loop
three
intracellular
loop
largest
famili
membran
receptor
coupl
intracellular
effector
system
via
g
protein
intravit
microscopi
ivm
realtim
qualit
quantit
method
observ
cellcel
interact
microcircul
anaesthet
anim
ischaemiareperfus
ir
contribut
pathophysiolog
mani
clinic
problem
myocardi
infarct
stroke
resuscit
coronari
bypass
surgeri
frostbit
extens
burn
injuri
organ
transplant
accord
american
heart
associ
million
peopl
suffer
heart
attack
year
approxim
suffer
stroke
diseas
significantli
contribut
mortal
rate
full
recoveri
unlik
singl
import
factor
degre
ischaem
damag
time
event
ischaemia
refer
reduct
blood
flow
reperfus
injuri
associ
initi
bloodborn
neutrophil
infiltr
give
rise
inflammatori
respons
final
result
tissu
injuri
although
restor
blood
flow
previous
ischaem
region
essenti
prevent
irrevers
tissu
damag
reperfus
doubleedg
sword
thu
alway
benefici
although
great
deal
damag
occur
tissu
reperfus
signific
amount
injuri
occur
due
ischaemia
myocardi
injuri
sever
event
occur
mediat
vascular
injuri
includ
oxygen
free
radic
product
mitochondri
respir
activ
neutrophil
xanthin
oxidas
activ
intim
involv
inflammatori
cascad
activ
leukocyt
induc
lipid
peroxid
increas
vascular
permeabl
leukocyt
recruit
occur
microvasculatur
involv
complex
set
event
occur
local
system
vivo
vitro
evid
eg
antibodi
adhes
molecul
chemotaxi
transmigr
assay
flow
chamber
assay
realtim
studi
visualis
cellular
interact
circul
anaesthetis
anim
use
intravit
microscopi
demonstr
molecular
cellular
pathway
involv
multistep
cascad
leukocyt
adhes
cascad
involv
captur
roll
slow
roll
leukocyt
arrest
postadhes
strengthen
intravascular
crawl
paracellular
transcellular
transmigr
figur
live
organ
capabl
recov
differ
pathogen
noxiou
stimuli
enter
system
injuri
bodi
provok
host
acut
inflammatori
respons
pain
fever
red
swell
case
chronic
inflamm
loss
function
inflammatori
respons
characteris
leukocyt
infiltr
achiev
integrin
adhes
selectin
glycoprotein
selectin
ligand
respons
cytokin
chemotact
factor
gradient
factor
mediat
inflammatori
cascad
involv
leukocyt
roll
adhes
transendotheli
migrat
figur
numer
receptor
modul
host
inflammatori
respons
abnorm
situat
bodi
respons
assum
charact
diseas
result
tissu
damag
observ
patholog
condit
ir
injuri
microvascular
dysfunct
observ
reperfus
ischaem
tissu
includ
endothelialdepend
dilat
arteriol
increas
fluid
filtrat
leukocyt
plug
capillari
lead
noreflow
phenomenon
basi
current
understand
ir
sever
potenti
treatment
suggest
base
mechan
eg
coronari
angioplasti
stent
pharmacolog
eg
antiplatelet
therapi
tissu
plasminogen
activ
administr
neutral
alreadi
secret
proinflammatori
cytokin
administr
antiinflammatori
cytokin
factor
favour
mesenchym
stem
cell
implant
mobil
restor
blood
flow
therapeut
approach
explor
target
receptor
implic
regul
resolv
inflamm
associ
ir
one
famili
receptor
gproteincoupl
receptor
gpcr
known
formyl
peptid
receptor
fpr
whose
involv
ir
injuri
demonstr
varieti
differ
tissu
thu
ligand
fpr
might
play
role
host
defens
fpr
promiscu
abil
bind
differ
ligand
formylmetleuph
fmlp
lipoxin
lxa
box
tabl
howev
receptor
express
differ
cell
tissu
rais
possibl
fpr
far
divers
complex
role
biolog
interestingli
resolut
inflamm
involv
format
endogen
antiinflammatori
mediat
signal
termin
recruit
remov
inflammatori
cell
inflammatori
locu
review
summaris
evid
propos
fpr
ligand
novel
antiinflammatori
proresolv
therapeut
focu
role
reduc
detriment
effect
associ
ir
injuri
fpr
famili
tissu
cellular
distribut
one
beststudi
gpcr
date
back
earli
activ
produc
rang
inflammatori
respons
associ
ir
stimul
leukocyt
migrat
found
varieti
differ
tissu
cell
tabl
figur
exampl
inflam
murin
mesenter
venul
pictur
demonstr
step
involv
inflammatori
cascad
leukocyt
captur
roll
slow
roll
arrest
postadhes
strengthen
intravascular
crawl
either
paracellular
ranscellular
migrat
leukocyt
surround
tissu
fpr
signal
leukocyt
respons
chemoattract
fmlp
requir
bind
activ
pertussintoxinsensit
gpcr
coupl
g
g
trigger
multipl
second
messeng
phospholipas
c
plc
pld
pla
activ
fmlp
stimul
leukocyt
induc
shape
chang
chemotaxi
adhes
phagocytosi
releas
superoxid
anion
granul
content
lead
tissu
damag
observ
inflamm
infarct
major
neutrophil
function
stimul
fmlf
inhibit
treatment
cell
pertussi
toxin
indic
fpr
belong
g
famili
heterotrimer
g
protein
three
human
fpr
cluster
chromosom
region
wherea
murin
equival
arrang
two
cluster
chromosom
togeth
addit
pseudogen
base
receptor
structur
receptor
agonist
tabl
human
tabl
demonstr
human
fpr
nomenclatur
share
sequenc
homolog
possess
high
degre
amino
acid
ident
activ
differ
ligand
tabl
gene
encod
put
protein
amino
acid
similar
nonhuman
high
degre
specif
human
orthologu
gene
occur
nonhuman
primat
situat
complic
mice
gene
cluster
undergon
differenti
expans
mous
genom
encod
least
seven
differ
receptor
tabl
agre
murin
ident
human
ident
human
bind
fmlf
low
affin
seem
direct
counterpart
human
genom
encod
receptor
short
coohtermin
domain
wherea
stop
codon
put
transmembran
domain
like
pseudogen
two
addit
gene
characteris
screen
mous
bac
genom
librari
term
orthologu
found
molecular
level
speci
rabbit
primat
function
level
rat
guinea
pig
hors
review
noteworthi
chemoattract
receptorlik
molecul
human
clone
high
aminoacid
homolog
member
fpr
famili
howev
similar
insuffici
classifi
fpr
member
trend
pharmacolog
scienc
vol
involv
inflamm
endotheli
cell
platelet
dendrit
cell
dc
possibl
import
modul
tcell
activ
equal
wide
distribut
interest
presenc
addit
peripher
cell
tissu
brain
spinal
cord
function
express
glial
cell
fibroblast
astrocyt
function
fpr
wide
express
nonlymphoid
tissu
includ
normal
human
lung
skin
fibroblast
human
fibrosarcoma
cell
line
van
compernol
demonstr
fibroblast
express
fpr
respond
chemoattract
manner
treatment
fmlp
thu
open
new
area
role
nonleukocyt
cell
type
innat
immun
respons
recent
review
seem
present
neutrophil
monocyt
fascinatingli
tissu
distribut
vari
monocyt
differenti
stage
matur
dc
mainli
express
cui
et
al
use
primari
microglia
cell
demonstr
express
gene
stimul
bacteri
lipopolysaccharid
lp
cell
undergo
activ
lead
suggest
blood
brain
barrier
bbb
normal
condit
protect
microgli
cell
endotoxaemia
occur
howev
microvessel
form
incomplet
bbb
lp
abl
stimul
microgli
cell
assum
macrophag
characterist
thu
play
role
inflammatori
process
increas
inflammatori
event
leukocyt
roll
adhes
occur
murin
cerebr
microcircul
endotoxaemia
someth
observ
normal
condit
seem
mediat
gavin
et
al
unpublish
observ
increas
inflammatori
event
leukocyt
roll
adhes
observ
follow
endotoxaemia
also
occur
stroke
role
alx
stroke
great
interest
research
team
import
receptor
potenti
therapeut
target
current
investig
role
fpr
cerebr
ir
discuss
detail
later
review
varieti
differ
agonist
antagonist
current
availbal
fpr
famili
tabl
possibl
cover
within
review
focuss
wide
use
one
emerg
sensit
techniqu
computerassist
model
help
us
understand
ligand
bind
differ
receptor
sever
natur
formyl
peptid
purifi
bacteri
supernat
exhibit
abil
activ
human
leukocyt
fmlp
wide
use
agonist
fpr
famili
bind
approxim
higher
affin
k
valu
picomolar
low
nanomolar
rang
result
calcium
mobil
neutrophil
activ
evid
suggest
activ
signal
respons
downstream
receptor
result
activ
produc
differ
ligand
lowaffin
receptor
fmlp
k
nm
produc
chemotact
respons
micromolar
concentr
k
valu
mm
lxa
also
interact
k
nm
inhibit
proinflammatori
respons
induc
alx
ligand
neutrophil
ligand
epitheli
cell
line
low
k
valu
demonstr
high
affin
receptor
characteris
fpr
interact
phagocyt
subsequ
cellular
activ
sever
fmlpome
analogu
synthes
includ
formetleuci
ome
cysleumetfpr
bind
recent
fmlpome
analogu
receptor
affin
greater
parent
fmlpome
synthes
creat
potenti
use
carrier
drug
construct
screen
random
peptid
librari
becom
use
tool
develop
biolog
activ
agent
wkymvm
stimul
human
b
lymphocyt
monocyt
cell
line
neutrophil
klein
isol
mani
small
peptid
sequenc
react
lesifrsllfrvm
potent
agonist
synthet
peptid
hfylpm
stimul
monocyt
neutrophil
via
bind
peptid
fragment
nadh
dehydrogenas
subunit
myfiniltl
agonist
specif
recent
screen
studi
includ
gpcr
screen
identifi
novel
peptid
agonist
term
tipmfvpestsklqkftswfmamid
screen
uniqu
nonpeptid
agonist
screen
demonstr
agonist
wide
chemic
divers
analysi
futur
agonist
enhanc
knowledg
ligandfpr
interact
exogen
endogen
ligand
interact
fpr
famili
one
particular
endogen
ligand
wide
studi
glucocorticoidregul
protein
annexin
counteract
leukocyt
extravas
figur
use
calcium
bind
assay
lselectin
shed
protocol
walther
et
al
demonstr
nterminalderiv
peptid
act
human
neutrophil
shown
peptid
initi
chemotact
respons
human
monocyt
desensit
cell
subsequ
stimul
endogen
ligand
physiolog
relev
involv
patholog
condit
acutephas
protein
serum
amyloid
saa
ab
prion
protein
fragment
found
prion
diseas
requir
high
micromolar
concentr
activ
serum
saa
concentr
increas
acutephas
respons
caus
tissu
organ
amyloidosi
chronic
inflamm
induc
chemotaxi
phagocyt
leukocyt
thought
pathophysiolog
concentr
saa
activ
alx
could
therefor
use
biomark
inflammatori
diseas
ab
enzymat
cleavag
fragment
amyloid
precursor
protein
app
aggreg
form
major
compon
senil
plaqu
found
brain
tissu
patient
alzheim
diseas
ad
ab
implic
neurodegener
proinflammatori
respons
observ
ad
activ
suggest
might
repres
potenti
therapeut
target
ad
treatment
stimul
human
monocyt
caus
intern
receptor
releas
proinflammatori
mediat
potenti
ligand
includ
hivenvelop
protein
f
peptid
interact
andor
interact
vitro
mous
vivo
use
higher
efficaci
overlap
signal
term
peptid
f
peptid
amino
acid
peptid
amino
acid
interact
helicobact
pylori
peptid
hp
also
act
via
induc
nadph
oxidas
activ
human
neutrophil
clear
larg
amount
research
still
ongo
perform
design
success
ligand
fpr
famili
key
aspect
process
reli
target
specif
name
ligand
high
affin
almost
affin
ligand
target
specif
also
reduc
risk
harm
side
effect
produc
exampl
nonspecif
bind
variou
antagonist
form
replac
nformyl
group
fmlp
tbutyloxycarbonyl
tboc
isopropyl
ureido
yield
peptid
block
fmlp
interact
receptor
sever
studi
use
boc
deriv
nonselect
antagonist
fpr
famili
member
demonstr
fpr
famili
involv
diseas
myocardi
infarct
stroke
select
antagonist
avail
chemotaxi
inhibitori
protein
staphylococcu
aureu
chip
present
clinic
strain
aureu
antagonis
complement
compon
receptor
specif
peptid
fragment
chip
ftfepfptneeiesn
select
anoth
protein
aureu
exhibit
select
bind
activ
inhibitori
protein
flipr
bind
directli
bile
acid
deoxychol
acid
dca
chenodeoxychol
acid
cdca
antagonis
possibl
suppress
antibacteri
respons
individu
cholestasi
dca
inhibit
fmlpinduc
monocyt
neutrophil
migrat
calcium
mobil
though
fmlp
bind
receptor
wherea
cdca
select
inhibit
monocyt
chemotaxi
calcium
flux
induc
fmlp
w
peptid
suggest
mechan
inhibit
inflamm
suppress
innat
immun
respons
synthet
nonpeptid
antagonist
develop
chemic
modif
agonist
although
differ
ligand
continu
identifi
fpr
clear
need
develop
potent
specif
agonist
antagonist
offer
greater
therapeut
potenti
devoid
major
side
effect
understand
complex
need
balanc
proand
antiinflammatori
pathway
retain
homeostat
environ
given
rise
great
number
possibl
drug
target
fpr
famili
particular
target
activ
endogen
antiinflammatori
mediat
could
use
drug
discoveri
ir
diseas
state
like
fewer
side
effect
applic
would
similar
mechan
bodi
use
reject
inflamm
one
particular
endogen
ligand
interest
protein
whose
involv
fpr
famili
wide
studi
afford
protect
number
ir
model
initi
cardioprotect
observ
rat
myocardi
ir
injuri
howev
la
et
al
investig
mechanist
molecular
basi
action
demonstr
pharmacophor
respons
cardioprotect
lie
within
amino
acid
correct
align
crucial
clinic
applic
hypothesis
basi
cardioprotect
retain
ntermin
peptid
also
term
administ
min
reperfus
administr
demonstr
first
time
fpr
involv
cardioprotect
properti
histolog
demonstr
neutrophil
influx
review
trend
pharmacolog
scienc
myocardium
induc
express
absent
sham
anim
although
rat
model
provid
novel
result
murin
model
particularli
use
given
current
knowledg
genom
eas
genet
manipul
tabl
mous
provid
evid
mediat
cardioprotect
afford
peptid
neutrophil
deplet
studi
affect
extent
acut
heart
injuri
affect
protect
afford
peptid
studi
provid
evid
role
mous
andor
circul
neutrophil
mediat
cardioprotect
sinc
report
provid
theoret
framework
consid
put
target
ir
injuri
publish
number
novel
ligand
identifi
peptid
agonist
cardioprotect
effect
rat
murin
myocardi
ir
reduc
infarct
size
respect
murin
troponin
level
thu
elicit
cardioprotect
similar
effect
report
agonist
studi
provid
evid
benefici
effect
pathway
inflamm
agonist
exhibit
protect
effect
ir
model
pfluorophenoxi
lxa
ester
fpho
lxa
protect
renal
ir
part
modul
cytokin
chemokin
express
neutrophil
recruit
first
evid
activ
aspirintrigg
lipoxin
provid
chiang
et
al
demonstr
protect
secondorgan
reperfus
injuri
novel
analogu
exhibit
inhibit
neutrophil
accumul
murin
hindlimb
irinduc
secondorgan
lung
injuri
intravit
microscopi
ivm
use
ir
studi
assess
effect
fpr
ligand
figur
ivm
realtim
qualit
quantit
method
observ
cellcel
interact
microcircul
anaesthet
anim
ir
studi
mesenteri
min
min
r
follow
mesenter
visual
use
ivm
mice
demonstr
one
fpr
famili
member
mediat
effect
peptid
possibl
includ
mous
effect
similar
observ
lpsinduc
damag
mous
mesenteri
hugh
et
al
unpublish
data
avail
genet
modifi
mice
facilit
characteris
understand
fpr
famili
differ
speci
remain
issu
howev
recent
studi
use
mice
ivm
reveal
mark
increas
inflamm
demonstr
increas
cell
adhes
emigr
follow
mesenter
ir
mice
also
augment
respons
carrageenaninduc
paw
edema
comparison
wildtyp
counterpart
studi
along
studi
laboratori
look
effect
stroke
mice
gavin
unpublish
data
demonstr
antiinflammatori
receptor
serv
function
host
defenc
respons
clear
ir
elicit
acut
inflammatori
respons
characteris
inflammatori
cell
recruit
oxid
stress
failur
endotheli
barrier
contribut
pathogenesi
mani
diseas
one
area
target
inflammatori
marker
fail
yield
success
therapeut
drug
candid
stroke
evid
fpr
agonist
possibl
novel
therapeut
target
treatment
cerebr
ir
injuri
discuss
cerebr
blood
flow
restor
follow
ischaemia
sever
cascad
initi
lead
activ
figur
schemat
fpr
agonist
could
reduc
inflamm
brain
follow
ir
injuri
exert
neuroprotect
neutrophil
activ
ir
injuri
roll
adher
migrat
tissu
releas
neutrophil
cytosol
granul
cell
surfac
interact
fpr
autocrin
paracrin
fashion
administr
ntermin
peptid
caus
leukocyt
detach
endotheli
cell
resid
cell
microglia
also
activ
ir
injuri
like
bloodborn
cell
releas
plethora
damag
mediat
reactiv
oxygen
speci
cytokin
tnfa
leukotrien
involv
process
might
similar
observ
peripher
microvasculatur
name
promot
resolut
receptor
mediat
process
stroke
remain
unknown
although
evid
suggest
fpralx
play
role
trend
pharmacolog
scienc
vol
bloodborn
resid
cell
microglia
astrocyt
neuron
actual
contribut
resid
cell
versu
bloodborn
cell
yet
fulli
quantifi
might
explain
clinic
trial
target
one
specif
aspect
inflammatori
cascad
fail
neuroprotect
role
mediat
via
fpr
demonstr
studi
use
middl
cerebr
arteri
occlus
model
combin
ivm
quantifi
cerebr
cellular
interact
follow
stroke
peptid
decreas
infarct
volum
leukocyt
adhes
marker
inflamm
microglia
might
part
contribut
inflammatori
respons
blood
cell
microglia
express
mous
might
mediat
effect
peptid
studi
studi
perform
valid
theori
current
data
suggest
microgli
cell
inhibit
reduc
brain
inflamm
postir
gavin
perretti
unpublish
data
figur
demonstr
could
act
autocrin
andor
paracrin
fashion
member
fpr
famili
reduc
inflamm
caus
detach
leukocyt
within
microvasculatur
ii
inhibit
product
cytotox
proinflammatori
mediat
activ
microgli
cell
thought
play
role
cerebrovascular
event
stroke
whether
mechan
mediat
inflammatori
respons
brain
observ
peripheri
remain
determin
like
similar
endogen
pathway
avail
throughout
host
mechan
action
inhibit
molecular
cellular
respons
ir
injuri
peptid
bioactiv
peptid
associ
fpr
could
repres
potenti
therapeut
target
neuroprotect
peptid
humanin
agonist
endogen
ligand
anoth
endogen
ligand
peptid
isol
human
haembind
protein
term
ac
weak
activ
activ
howev
agonist
bind
activ
receptor
concentr
low
nanomolar
rang
review
drawn
togeth
compel
evid
suggest
ligand
fpr
could
provid
novel
antiinflammatori
proresolv
therapeut
reduc
damag
associ
ir
injuri
promiscu
receptor
bind
differ
ligand
coupl
presenc
differ
cell
tissu
indic
divers
role
multipl
biolog
set
improv
understand
fundament
function
would
instruct
therapeut
target
identif
drug
develop
thu
studi
endogen
antiinflammatori
agonist
lipoxin
could
lead
identif
develop
better
therapeut
capabl
limit
detriment
effect
ir
injuri
promot
resolut
fewer
side
effect
